Several justices questioned the remedy of applying nationwide restrictions to mifepristone because it would be the first time a court had second-guessed the F.D.A.’s regulatory authority.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
